Quibim, a Valencia, Spain-based healthtech company for precision medicine, raised $50M in funding.
The round was led by Asabys (through its fund Sabadell Asabys II) and Buenavista Equity Partners (through the BHG I fund, created in partnership with Columbus Venture Partners), and joined by UI Investissements, and GoHub Ventures as new investors. It was also joined by current investors, Amadeus Capital Partners, APEX Ventures, Partech, Adara Ventures, Leadwind (KFund’s early growth fund) and Tony Fadell’s Build Collective, and individual investor Dr. Jonathan Milner, founder of Abcam plc.
The company intends to use the funds to consolidate its U.S. presence through strategic collaborations with hospitals and pharmaceutical companies.
Led by CEO Dr. Ángel Alberich-Bayarri, Quibim is a healthtech company pioneering tools that unlock imaging data to improve patient outcomes. It leverages the capabilities of MRI, CT, and PET imaging to create regulatory-cleared medical devices that are integrated into the workflows of healthcare providers worldwide. More than 170 healthcare institutions, research centres, hospitals, and clinical facilities are using its products globally.
In addition, the company has partnerships with Merck KGaA to develop imaging biomarker models to predict responses of cancer patients to immunotherapy and inform decisions in its global drug development efforts and with Phillips to launch AI-based imaging and reporting solutions for MRI prostate exams.
Quibim’s product portfolio includes:
- QP-Prostate®: the company’s flagship product is designed to enhance prostate cancer detection through an AI-powered lesion detection. CE, UKCA marked and 510(k) cleared.
- QP-Brain®: AI-based early-stage neurological disease quantification software for quantification of early brain atrophy and lesions. CE, UKCA marked and 510(k) cleared.
- QP-Liver®: automated AI tool for MR diagnosis of diffuse liver diseases through accurate quantification of tissue fat and iron levels. CE and UKCA marked.
- QP-Insights®: A platform to manage, store and analyse multi-omics data in clinical trials and real-world data studies. QP-Insights is being used by global biopharmaceutical companies, academic medical centres and research consortiums, including the European Cancer Imaging Initiative to support Europe’s Beating Cancer Plan. QP-Insights is the platform managing the largest imaging datasets in the world, accounting for more than 100 million medical images.
It has offices in New York City, US, Cambridge, UK, Valencia, Madrid, and Barcelona, Spain.
FinSMEs
28/01/2025